FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2086320859> ?p ?o ?g. }

• W2086320859 endingPage "904" @default.
• W2086320859 startingPage "896" @default.
• W2086320859 abstract "Cholangiocarcinoma is a highly malignant tumor with limited therapeutic options. We have previously reported that tamoxifen (TMX) induces apoptosis of cholangiocarcinoma cells and reduces cholangiocarcinoma tumorigenesis in mice. In the present studies, we determined the effect of combination therapy of TMX and gemcitabine (GMT), another chemotherapeutical reagent for many cancers, on cholangiocarcinoma tumorigenesis and investigated the responsible mechanisms. GMT inhibited cell growth and induced apoptosis of cholangiocarcinoma cells in a concentration-dependent manner. TMX enhanced GMT-induced apoptosis of cholangiocarcinoma cells. Consistently, GMT (15 mg/kg) inhibited cholangiocarcinoma tumorigenesis in nude mice by 50%. TMX (15 mg/kg) enhanced the inhibitory effect of GMT on tumorigenesis by 33%. The inhibition of tumor growth correlated with enhanced apoptosis in tumor tissues. To elucidate the mechanisms underlying the additive effects of TMX on GMT-induced apoptosis, we determined the activation of caspases in cholangiocarcinoma cells exposed to GMT, TMX, or both. Activation of caspases 9 and 3, as well as cytochrome c release to the cytosol, was demonstrated in cells exposed to both reagents. In contrast, TMX activated caspase 2, whereas GMT had no effect. Inhibition of caspase 2 activation decreased TMX-, but not GMT-, induced activation of caspase 3 and apoptosis of cholangiocarcinoma cells. Similarly, activation of caspase 2 was found in tumors from TMX-treated mice, but not GMT-treated mice. Therefore, the enhanced effect of TMX on GMT-induced cholangiocarcinoma cell death is partially mediated by activation of caspase 2. TMX and GMT both induce apoptosis and inhibit cholangiocarcinoma tumorigenesis, which may be attributed to the activation of distinct apoptosis signals by TMX and GMT. Our studies provide in vivo evidence and molecular insight to support the use of TMX and GMT in combination as an effective therapy for cholangiocarcinoma." @default.
• W2086320859 created "2016-06-24" @default.
• W2086320859 creator A5001606544 @default.
• W2086320859 creator A5008301926 @default.
• W2086320859 creator A5010289974 @default.
• W2086320859 creator A5038178209 @default.
• W2086320859 creator A5038598323 @default.
• W2086320859 creator A5044844284 @default.
• W2086320859 creator A5063519178 @default.
• W2086320859 creator A5072740925 @default.
• W2086320859 date "2011-06-01" @default.
• W2086320859 modified "2023-09-27" @default.
• W2086320859 title "Tamoxifen enhances therapeutic effects of gemcitabine on cholangiocarcinoma tumorigenesis" @default.
• W2086320859 cites W1534102370 @default.
• W2086320859 cites W161836838 @default.
• W2086320859 cites W1741559726 @default.
• W2086320859 cites W1911108481 @default.
• W2086320859 cites W1942214720 @default.
• W2086320859 cites W1963767651 @default.
• W2086320859 cites W1966216790 @default.
• W2086320859 cites W1977956466 @default.
• W2086320859 cites W1980168971 @default.
• W2086320859 cites W1986473514 @default.
• W2086320859 cites W1987022495 @default.
• W2086320859 cites W1992076003 @default.
• W2086320859 cites W1997341743 @default.
• W2086320859 cites W1997879915 @default.
• W2086320859 cites W1999202100 @default.
• W2086320859 cites W2006752784 @default.
• W2086320859 cites W2009626612 @default.
• W2086320859 cites W2020555834 @default.
• W2086320859 cites W2022145079 @default.
• W2086320859 cites W2033458863 @default.
• W2086320859 cites W2040883058 @default.
• W2086320859 cites W2042162210 @default.
• W2086320859 cites W2048263113 @default.
• W2086320859 cites W2050129947 @default.
• W2086320859 cites W2053885863 @default.
• W2086320859 cites W2056919940 @default.
• W2086320859 cites W2066834207 @default.
• W2086320859 cites W2071154359 @default.
• W2086320859 cites W2078797029 @default.
• W2086320859 cites W2092058250 @default.
• W2086320859 cites W2096888043 @default.
• W2086320859 cites W2103911973 @default.
• W2086320859 cites W2105069386 @default.
• W2086320859 cites W2110506515 @default.
• W2086320859 cites W2112589532 @default.
• W2086320859 cites W2113988779 @default.
• W2086320859 cites W2115475846 @default.
• W2086320859 cites W2117050193 @default.
• W2086320859 cites W2119812397 @default.
• W2086320859 cites W2120713127 @default.
• W2086320859 cites W2121232458 @default.
• W2086320859 cites W2121415861 @default.
• W2086320859 cites W2127024723 @default.
• W2086320859 cites W2132604531 @default.
• W2086320859 cites W2156390455 @default.
• W2086320859 cites W39641639 @default.
• W2086320859 cites W4211234270 @default.
• W2086320859 cites W4234577872 @default.
• W2086320859 cites W4239636442 @default.
• W2086320859 cites W4246018467 @default.
• W2086320859 cites W4248537801 @default.
• W2086320859 cites W4312472830 @default.
• W2086320859 cites W91452638 @default.
• W2086320859 doi "https://doi.org/10.1038/labinvest.2011.60" @default.
• W2086320859 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21464824" @default.
• W2086320859 hasPublicationYear "2011" @default.
• W2086320859 type Work @default.
• W2086320859 sameAs 2086320859 @default.
• W2086320859 citedByCount "15" @default.
• W2086320859 countsByYear W20863208592012 @default.
• W2086320859 countsByYear W20863208592013 @default.
• W2086320859 countsByYear W20863208592014 @default.
• W2086320859 countsByYear W20863208592015 @default.
• W2086320859 countsByYear W20863208592016 @default.
• W2086320859 countsByYear W20863208592017 @default.
• W2086320859 countsByYear W20863208592018 @default.
• W2086320859 countsByYear W20863208592021 @default.
• W2086320859 countsByYear W20863208592022 @default.
• W2086320859 crossrefType "journal-article" @default.
• W2086320859 hasAuthorship W2086320859A5001606544 @default.
• W2086320859 hasAuthorship W2086320859A5008301926 @default.
• W2086320859 hasAuthorship W2086320859A5010289974 @default.
• W2086320859 hasAuthorship W2086320859A5038178209 @default.
• W2086320859 hasAuthorship W2086320859A5038598323 @default.
• W2086320859 hasAuthorship W2086320859A5044844284 @default.
• W2086320859 hasAuthorship W2086320859A5063519178 @default.
• W2086320859 hasAuthorship W2086320859A5072740925 @default.
• W2086320859 hasBestOaLocation W20863208591 @default.
• W2086320859 hasConcept C121608353 @default.
• W2086320859 hasConcept C126322002 @default.
• W2086320859 hasConcept C185592680 @default.
• W2086320859 hasConcept C190283241 @default.
• W2086320859 hasConcept C2777176818 @default.
• W2086320859 hasConcept C2780258809 @default.
• W2086320859 hasConcept C31573885 @default.

• next